Literature DB >> 22779202

Management of the oral sequelae of cancer therapy.

Daniel L Jones1, K Vendrell Rankin.   

Abstract

Oral cancer and the oral sequelae of treatment for oral and other malignancies can significantly affect a patient's oral and systemic health, as well as have a profound impact on quality of life. Compromised oral health prior to, during, and following cancer therapy can affect treatment outcomes. Increasingly, dental professionals in the community are being called upon to provide care for these individuals. Radiation therapy is routinely used for tumors of the head and neck, delivering a concentrated radiation dose to the tumor, but also to the immediately surrounding tissue. Oral complications are related to the site radiated and the total radiation dose. Cancer chemotherapy is provided as a primary treatment for some cancers and as an adjunctive modality for other cancers. The goal is to eradicate the rapidly growing cells of the tumor, but chemotherapy is often toxic to other cells that rapidly divide normally including the oral mucosa. The use of combined chemotherapy and radiation is now considered standard for most locally advanced tumors of the head and neck. The toxicities of this combined therapy are essentially the same as with radiation alone, but develop more rapidly and are typically more severe when they reach maximum level. The most common oral sequelae of cancer treatment are: xerostomia, the sensation of a dry mouth as a result of damage to the salivary glands and/or medication; mucositis, the inflammation and ulceration of the oral mucosa; and infection as a result of the loss of mucosal integrity. Management of oral health during cancer therapy includes identifying at-risk patients, patient education, appropriate pretreatment interventions, and timely management of complications. Appropriate preventive and therapeutic measures will help minimize the risk of oral and associated systemic complications, improve treatment outcomes, and improve the patient's quality of life.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22779202

Source DB:  PubMed          Journal:  Tex Dent J        ISSN: 0040-4284


  6 in total

Review 1.  Appropriate and necessary oral care for people with cancer: guidance to obtain the right oral and dental care at the right time.

Authors:  Joel B Epstein; Pelin Güneri; Andrei Barasch
Journal:  Support Care Cancer       Date:  2014-03-28       Impact factor: 3.603

2.  Dental students' knowledge of characteristics and management of oral complications of cancer therapy.

Authors:  Esin Alpöz; Pelin Güneri; Joel B Epstein; Hülya Cankaya; Damir Osmic; Hayal Boyacıoğlu
Journal:  Support Care Cancer       Date:  2013-06-01       Impact factor: 3.603

3.  Functional and quality of life outcomes after partial glossectomy: a multi-institutional longitudinal study of the head and neck research network.

Authors:  Agnieszka Dzioba; Daniel Aalto; Georgina Papadopoulos-Nydam; Hadi Seikaly; Jana Rieger; Johan Wolfaardt; Martin Osswald; Jeffrey R Harris; Daniel A O'Connell; Cathy Lazarus; Mark Urken; Ilya Likhterov; Raymond L Chai; Erika Rauscher; Daniel Buchbinder; Devin Okay; Risto-Pekka Happonen; Ilpo Kinnunen; Heikki Irjala; Tero Soukka; Juhani Laine
Journal:  J Otolaryngol Head Neck Surg       Date:  2017-09-04

4.  The effect of a single injection of irinotecan on the development of enamel in the Wistar rats.

Authors:  Sali Al-Ansari; Rozita Jalali; Ton Bronckers; Judith Raber-Durlacher; Richard Logan; Jan de Lange; Frederik Rozema
Journal:  J Cell Mol Med       Date:  2017-12-28       Impact factor: 5.310

5.  Factors Associated with Unmet Dental Care Needs among Korean Adult Cancer Survivors: Cross-Sectional Analysis of the 2016-2018 KNHANES.

Authors:  So-Yeong Kim; Sun-A Lim
Journal:  Healthcare (Basel)       Date:  2022-08-18

Review 6.  Dental anomalies in children submitted to antineoplastic therapy.

Authors:  Camila Merida Carrillo; Fernanda Nahás Pires Corrêa; Nilza Nelly Fontana Lopes; Marcelo Fava; Vicente Odone Filho
Journal:  Clinics (Sao Paulo)       Date:  2014-06       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.